Compare MMYT & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | TLX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | India | Australia |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2010 | 2024 |
| Metric | MMYT | TLX |
|---|---|---|
| Price | $51.41 | $9.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $67.70 | $19.90 |
| AVG Volume (30 Days) | ★ 946.6K | 320.2K |
| Earning Date | 10-26-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.73 | $16.59 |
| Revenue Next Year | $16.45 | $13.64 |
| P/E Ratio | ★ $107.67 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.67 | $6.28 |
| 52 Week High | $86.94 | $13.11 |
| Indicator | MMYT | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 61.20 | 41.71 |
| Support Level | $48.34 | $8.69 |
| Resistance Level | $59.43 | $9.70 |
| Average True Range (ATR) | 2.37 | 0.23 |
| MACD | 0.86 | 0.06 |
| Stochastic Oscillator | 86.46 | 31.90 |
MakeMyTrip Ltd is an online travel company that provides online booking solutions for day-to-day travel needs. The company's operating segments include Air ticketing; Hotels and packages; Bus ticketing; and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segment includes internet-based platforms, call centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms and provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States, Singapore, United Arab Emirates, Saudi Arabia, and many others.
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.